# A Study of CL-197 Capsules in Healthy Participants

> **NCT05944848** · PHASE1 · COMPLETED · sponsor: **Henan Genuine Biotech Co., Ltd.** · enrollment: 44 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** 1 mg CL-197 capsules
- **DRUG:** 10 mg CL-197 capsules or CL-197 placebo
- **DRUG:** 30 mg CL-197 capsules or CL-197 placebo
- **DRUG:** 60 mg CL-197 capsules or CL-197 placebo
- **DRUG:** 100 mg CL-197 capsules or CL-197 placebo

## Key facts

- **NCT ID:** NCT05944848
- **Lead sponsor:** Henan Genuine Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-16
- **Primary completion:** 2024-01-20
- **Final completion:** 2024-01-20
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05944848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05944848, "A Study of CL-197 Capsules in Healthy Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05944848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*